Literature DB >> 5337357

Endocrine-induced regression of cancers.

C Huggins.   

Abstract

Cancer is not necessarily autonomous and intrinsically self-perpetuating. Its growth can be sustained and propagated by hormonal function in the host which is not unusual in kind or exaggerated in rate but which is operating at normal or even subnormal levels. Hormones, or synthetic substances inducing physiologic effects similar thereto, are of crucial significance for survival of several kinds of hormone-responsive cancers in man and animals. Opposite sorts of change of the hormonal status can induce regression and, in some instances, cure such cancers. These modifications are deprivation of essential hormones and hormone interference by giving large amounts of critical compounds. The control of cancer by endocrine methods can be described in three propositions: (i) Some types of cancer cells differ in a cardinal way from the cells from which they arose in their response to change in their hormonal environment. (ii) Certain cancers are hormone-dependent and these cells die when supporting hormones are eliminated. (iii) Certain cancers succumb when large amounts of hormones are administered.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 5337357     DOI: 10.1126/science.156.3778.1050

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  28 in total

1.  Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.

Authors:  Vanessa Fritz; Zohra Benfodda; Geneviève Rodier; Corinne Henriquet; François Iborra; Christophe Avancès; Yves Allory; Alexandre de la Taille; Stéphane Culine; Hubert Blancou; Jean Paul Cristol; Françoise Michel; Claude Sardet; Lluis Fajas
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

2.  Role of androgen ablation with low-dose-rate brachytherapy in the treatment of prostate cancer.

Authors:  Ashesh B Jani; Asal Shoushtari; Jeffrey M Feinstein
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

3.  Disodium pentaborate decahydrate (DPD) induced apoptosis by decreasing hTERT enzyme activity and disrupting F-actin organization of prostate cancer cells.

Authors:  Mehmet Korkmaz; Cigir Biray Avcı; Cumhur Gunduz; Duygu Aygunes; Burcu Erbaykent-Tepedelen
Journal:  Tumour Biol       Date:  2014-02

4.  Marshall R. Urist and the discovery of bone morphogenetic proteins.

Authors:  Lovorka Grgurevic; Marko Pecina; Slobodan Vukicevic
Journal:  Int Orthop       Date:  2017-02-11       Impact factor: 3.075

5.  Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.

Authors:  Jean-Sébastien Annicotte; Irena Iankova; Stéphanie Miard; Vanessa Fritz; David Sarruf; Anna Abella; Marie-Laurence Berthe; Danièle Noël; Arnaud Pillon; François Iborra; Pierre Dubus; Thierry Maudelonde; Stéphane Culine; Lluis Fajas
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

Review 6.  Carcinogenesis explained within the context of a theory of organisms.

Authors:  Carlos Sonnenschein; Ana M Soto
Journal:  Prog Biophys Mol Biol       Date:  2016-08-03       Impact factor: 3.667

Review 7.  Antineoplastic and immunosuppressive drugs. I. Biochemical and clinical pharmacological considerations.

Authors:  A H Chalmers; L A Burgoyne; A W Murray
Journal:  Drugs       Date:  1972       Impact factor: 9.546

8.  [Regulation of tumor growth by adenosine-3',5'-monophosphate].

Authors:  P Chandra; D Gericke
Journal:  Naturwissenschaften       Date:  1972-05

Review 9.  Management strategies for locally advanced prostate cancer.

Authors:  Ashesh B Jani
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

10.  miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.

Authors:  Cyrielle Clapé; Vanessa Fritz; Corinne Henriquet; Florence Apparailly; Pedro Luis Fernandez; François Iborra; Christophe Avancès; Martin Villalba; Stéphane Culine; Lluis Fajas
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.